Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers : Implications of BNP, H-FABP, and PTX3

概要

論文の詳細を見る
Background B-type natriuretic peptide (BNP), heart-type fatty acid-binding protein (H-FABP), and pentraxin 3 (PTX3) each predict adverse cardiac events in chronic heart failure (CHF) patients. For prognostic evaluation from different aspects, the utility of combined measurement of the 3 biomarkers in patients with CHF was examined in the present study. Methods and Results Levels of BNP (associated with left ventricular dysfunction, positive if >200pg/ml), H-FABP (marker of myocardial damage, positive if >4.1ng/ml), and PTX3 (marker of inflammation, positive if >4.0ng/ml) were measured in 164 consecutive CHF patients, and patients were prospectively followed with endpoints of cardiac death or rehospitalization. When patients were categorized on the basis of the number of elevated biomarkers, patients with 1,2, and 3 elevated biomarkers had a 5.4-fold (not significant), 11.2-old (p<0.05), and 34.6-fold increase (p<0.01), respectively, in the risk of adverse cardiac events compared with those without elevated biomarkers. Kaplan-Meier analysis revealed that patients with 3 elevated biomarkers had a significantly higher cardiac event rate than patients with a lower number of elevated biomarkers. Conclusion The combination of these 3 biomarkers could reliably risk-stratify CHF patients for prediction of cardiac events.
社団法人日本循環器学会の論文
2008-10-20